Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IBIO NASDAQ:LONA NASDAQ:PEPG NASDAQ:PLUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIBIOiBio$1.90-1.6%$1.87$0.56▼$3.82$95.88M1.23869,467 shs317,627 shsLONAAthira Pharma$9.54-1.0%$9.71$2.73▼$14.21$90.55M1.9842,626 shs9,795 shsPEPGPepGen$1.50$2.13$1.01▼$7.80$103.75M2.01856,606 shs596,057 shsPLURPluri$2.32-1.3%$3.18$2.22▼$5.96$25.35M0.7514,020 shs31,238 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIBIOiBio-1.55%+3.26%+17.28%-32.62%+189,999,900.00%LONAAthira Pharma-1.04%-7.65%+8.78%+69.45%+953,999,900.00%PEPGPepGen0.00%-0.66%-3.23%-75.88%-5.06%PLURPluri-1.28%-2.11%-30.02%-35.56%-49.12%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIBIOiBio$1.90-1.6%$1.87$0.56▼$3.82$95.88M1.23869,467 shs317,627 shsLONAAthira Pharma$9.54-1.0%$9.71$2.73▼$14.21$90.55M1.9842,626 shs9,795 shsPEPGPepGen$1.50$2.13$1.01▼$7.80$103.75M2.01856,606 shs596,057 shsPLURPluri$2.32-1.3%$3.18$2.22▼$5.96$25.35M0.7514,020 shs31,238 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIBIOiBio-1.55%+3.26%+17.28%-32.62%+189,999,900.00%LONAAthira Pharma-1.04%-7.65%+8.78%+69.45%+953,999,900.00%PEPGPepGen0.00%-0.66%-3.23%-75.88%-5.06%PLURPluri-1.28%-2.11%-30.02%-35.56%-49.12%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIBIOiBio 3.17Buy$4.75150.00% UpsideLONAAthira Pharma 2.40Hold$15.0057.23% UpsidePEPGPepGen 2.67Moderate Buy$11.60673.33% UpsidePLURPluri 2.00Hold$12.00417.24% UpsideCurrent Analyst Ratings BreakdownLatest PLUR, PEPG, LONA, and IBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2026LONAAthira Pharma Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$20.005/21/2026PEPGPepGen HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/19/2026PLURPluri Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/13/2026PEPGPepGen WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$5.00 ➝ $4.005/11/2026LONAAthira Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/1/2026PLURPluri Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026PEPGPepGen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/9/2026IBIOiBio Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.003/31/2026PEPGPepGen WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$9.00 ➝ $5.003/27/2026IBIOiBio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/18/2026IBIOiBio Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.00(Data available from 5/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIBIOiBio$400K235.98N/AN/A$1.56 per share1.22LONAAthira PharmaN/AN/AN/AN/A$5.25 per shareN/APEPGPepGenN/AN/AN/AN/A$1.94 per shareN/APLURPluri$1.34M18.68N/AN/A($1.20) per share-1.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIBIOiBio-$18.38M-$0.58N/AN/AN/AN/A-53.86%-46.48%N/ALONAAthira Pharma-$105.61M-$5.21N/AN/AN/AN/A-381.01%-225.74%N/APEPGPepGen-$89.65M-$1.75N/AN/AN/AN/A-59.89%-49.62%8/6/2026 (Estimated)PLURPluri-$22.58M-$4.53N/AN/AN/A-2,162.08%N/A-106.59%N/ALatest PLUR, PEPG, LONA, and IBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q3 2026PLURPluri-$0.66-$0.55+$0.11-$0.55$0.66 million$0.17 million5/12/2026Q3 2026IBIOiBio-$0.06-$0.07-$0.01-$0.06$0.02 millionN/A5/12/2026Q1 2026PEPGPepGen-$0.31-$0.26+$0.05-$0.26N/AN/A5/7/2026Q1 2026LONAAthira PharmaN/A-$1.73N/A-$1.73N/AN/A3/26/2026Q4 2025LONAAthira PharmaN/A-$18.90N/A-$18.90N/AN/A3/4/2026Q4 2025PEPGPepGen-$0.40-$0.27+$0.13-$0.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIBIOiBioN/AN/AN/AN/AN/ALONAAthira PharmaN/AN/AN/AN/AN/APEPGPepGenN/AN/AN/AN/AN/APLURPluriN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIBIOiBioN/A11.8811.88LONAAthira PharmaN/A10.3810.38PEPGPepGenN/A14.9814.98PLURPluriN/A0.330.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIBIOiBio7.90%LONAAthira Pharma57.12%PEPGPepGen58.01%PLURPluri16.59%Insider OwnershipCompanyInsider OwnershipIBIOiBio2.75%LONAAthira Pharma25.73%PEPGPepGen1.30%PLURPluri25.93%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIBIOiBio10049.68 million48.31 millionN/ALONAAthira Pharma409.39 million6.98 millionN/APEPGPepGen3069.17 million68.27 millionNot OptionablePLURPluri15010.79 million7.99 millionNo DataPLUR, PEPG, LONA, and IBIO HeadlinesRecent News About These CompaniesPluri Insider Ups Holding During YearMay 28 at 5:51 PM | finance.yahoo.comPluri Analyst Ratings and Price Targets | NASDAQ:PLUR | BenzingaMay 19, 2026 | benzinga.comNewcelX and Eledon Pharmaceuticals Collaborate on NCEL-101 for Type 1 Diabetes, Reporting Strong Financial Position and Strategic Growth PlansApril 30, 2026 | quiverquant.comQPluri Announces Financing Through Unregistered Equity Securities DealMarch 27, 2026 | tipranks.comPluri Inc.: Pluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private PlacementMarch 26, 2026 | finanznachrichten.dePluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private PlacementMarch 26, 2026 | finance.yahoo.comPluri Regains Nasdaq Compliance, Restoring Listing StabilityMarch 2, 2026 | tipranks.comPluri Biotech Secures China Patent for Immune Cell TechFebruary 18, 2026 | contractpharma.comCPluri Secures Global IP Position with China Patent Grant for Large-Scale Immune Cell Expansion, Complementing Prior U.S. PatentFebruary 18, 2026 | markets.businessinsider.comPluri's cell therapy to extends lifespan and combat chronic diseaseFebruary 17, 2026 | i24news.tvIPluri showcases cell expansion platform as Resbiomed program advancesFebruary 10, 2026 | finance.yahoo.comPluri's Alejandro Weinstein on the future of cell-based technologyFebruary 2, 2026 | msn.comPluri Faces Nasdaq Noncompliance Notice, Evaluating Listing OptionsJanuary 22, 2026 | tipranks.comPluri Successfully Completes First Phase of Resbiomed Program for Placenta-Derived Collagen-Rich BiomaterialsJanuary 22, 2026 | markets.businessinsider.comPluri, Inc. Completes First Phase of Regenerative Medicine Collaboration with Resbiomed TechnologiesJanuary 22, 2026 | quiverquant.comQPluri announces expansion of manufacturing agreement with Remedy CellDecember 22, 2025 | msn.comPluri, Inc. Expands Manufacturing Agreement with Remedy Cell Ltd. for Clinical Development of Cell-Free TherapeuticsDecember 22, 2025 | quiverquant.comQPluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing AchievedDecember 22, 2025 | globenewswire.comA US$3.4m Market Cap Boost Pleasing ToPluri InsidersDecember 19, 2025 | finance.yahoo.comPluri appoints Weinstein as chairman of the board of directorsDecember 10, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePLUR, PEPG, LONA, and IBIO Company DescriptionsiBio NASDAQ:IBIO$1.90 -0.03 (-1.55%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$1.90 +0.01 (+0.26%) As of 05/29/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.Athira Pharma NASDAQ:LONA$9.54 -0.10 (-1.04%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$9.63 +0.09 (+0.94%) As of 05/29/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.PepGen NASDAQ:PEPG$1.50 0.00 (0.00%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$1.54 +0.04 (+2.67%) As of 05/29/2026 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.Pluri NASDAQ:PLUR$2.32 -0.03 (-1.28%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$2.26 -0.06 (-2.59%) As of 05/29/2026 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/25 - 05/29 Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17% Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem MongoDB's AI Advantage Is Starting to Show Up in Results Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Dollar Tree Keeps Winning After Family Dollar Divorce Salesforce Stock Finds Support as AI Momentum Builds These 3 Software Stocks Are Buying Back Shares Hand Over Fist Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
